Cyclosporine refuses to retire. Despite being introduced into clinical practice in the 1970s and facing competition from newer immunosuppressants like tacrolimus and biologics, cyclosporine remained the 179th most commonly prescribed medication in the United States in 2023, with more than 2 million prescriptions filled. The drug persists because it occupies a unique position in medicine — it is cheap in generic form, has decades of well-understood safety monitoring data, and serves a remarkably broad range of conditions from organ transplant rejection to dry eye disease. The reasons cyclosporine has not been displaced are more nuanced than simple institutional inertia. Newer drugs sometimes trade one set of problems for another.
Tacrolimus, for example, reduces acute organ rejection more effectively but causes significantly higher rates of post-transplant diabetes. In resource-limited countries, generic cyclosporine costs a fraction of what newer alternatives run, making it the only realistic option for millions of transplant recipients. And in ophthalmology, cyclosporine eye drops remain a cornerstone treatment that newer competitors have not managed to unseat. This article examines the specific clinical, economic, and practical reasons cyclosporine endures. We will look at head-to-head data against tacrolimus, the drug’s surprisingly broad list of approved and off-label uses, its role in developing nations, the ophthalmic market where it dominates dry eye treatment, and what all of this means for patients and caregivers navigating treatment decisions — including those managing neurological and cognitive conditions where immunosuppression plays a role.
Table of Contents
- What Keeps Cyclosporine in Use When Newer Immunosuppressants Exist?
- The Breadth of Cyclosporine’s Approved and Off-Label Uses
- How Decades of Monitoring Data Create a Clinical Safety Net
- The Cost Factor — Why Generic Cyclosporine Dominates in Much of the World
- Cyclosporine in Dry Eye Treatment — A Separate Market Entirely
- Neurological Side Effects — What Caregivers Should Watch For
- Where Cyclosporine Goes From Here
- Conclusion
- Frequently Asked Questions
What Keeps Cyclosporine in Use When Newer Immunosuppressants Exist?
The short answer is that newer does not automatically mean better for every patient. Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation, a mechanism thoroughly characterized over nearly five decades of clinical use. That long track record is itself a clinical asset. More than 65% of healthcare providers incorporate cyclosporine into long-term therapeutic regimens, according to industry market data from GM Insights. Physicians know exactly how to monitor it, when to adjust doses, and what side effects to watch for — a level of familiarity that reduces errors and improves outcomes in practice. Consider the comparison with tacrolimus, which is often presented as cyclosporine’s successor in transplant medicine. A Cochrane systematic review found that tacrolimus does reduce acute rejection by roughly 12 additional cases per 100 kidney transplant patients compared to cyclosporine.
That is a meaningful benefit. But the same review found tacrolimus causes 5 additional cases of insulin-requiring diabetes per 100 patients, along with higher rates of neurological and gastrointestinal side effects. For a patient who already has diabetes risk factors or who is managing neurological symptoms — including cognitive decline — that tradeoff may not be worth it. This is precisely why cyclosporine has not vanished from transplant protocols. Some patients genuinely do better on the older drug. In lung transplantation, cyclosporine was associated with a modestly increased risk of chronic lung allograft dysfunction (hazard ratio 1.16, 95% CI 1.08–1.23, p < 0.001), but certain transplant centers still use it specifically for patients who cannot tolerate tacrolimus's side-effect profile. Medicine is not a one-size-fits-all enterprise, and cyclosporine's persistence reflects that reality.
The Breadth of Cyclosporine’s Approved and Off-Label Uses
One reason cyclosporine remains difficult to displace is that it treats an unusually wide range of conditions. Its FDA-approved indications include prevention of organ transplant rejection in kidney, liver, and heart allografts — its original and most established use. It is also approved for rheumatoid arthritis in patients who have failed methotrexate and other first-line disease-modifying antirheumatic drugs, and for severe plaque psoriasis in adults who have failed at least one systemic therapy. In ophthalmology, cyclosporine eye drops such as Restasis (0.05%) and Cequa (0.09%) are approved to increase tear production in patients with keratoconjunctivitis sicca, or chronic dry eye disease. The off-label list is even longer. Clinicians prescribe cyclosporine for ulcerative colitis, nephrotic syndrome, uveitis, Behçet disease, graft-versus-host disease, and atopic dermatitis, among other conditions. Each of these uses has its own body of supporting evidence and its own community of prescribers who know the drug well.
Displacing cyclosporine from all of these niches simultaneously would require not one superior alternative but many — each proven in its specific indication. However, this breadth comes with a caveat. Cyclosporine is not a gentle medication. Its most serious risk is nephrotoxicity, which is why therapeutic drug monitoring is mandatory for systemic use. Patients on cyclosporine need regular blood level checks and kidney function tests. If a patient has pre-existing kidney disease, the risk-benefit calculation shifts considerably, and newer alternatives with different toxicity profiles may genuinely be preferable. The drug’s versatility does not make it universally appropriate.
How Decades of Monitoring Data Create a Clinical Safety Net
One of cyclosporine’s most underappreciated advantages is the sheer volume of therapeutic drug monitoring data that has accumulated since the 1970s. According to a 2024 review published in ScienceDirect, cyclosporine’s pharmacokinetics are so well characterized that dose adjustments to prevent nephrotoxicity and acute rejection are predictable and well-understood. Clinicians have access to established therapeutic ranges, validated assays, and decades of published experience with drug-drug interactions. This matters more than it might seem.
When a physician prescribes cyclosporine today, they are not navigating uncharted territory. They know, for example, that grapefruit juice increases cyclosporine blood levels, that certain antibiotics and antifungals interact with it through the cytochrome P450 system, and that blood trough levels need to be maintained within specific ranges depending on the indication and time since transplant. This depth of knowledge reduces the likelihood of dosing errors and adverse events. For caregivers of patients with dementia or cognitive impairment who also require immunosuppression — say, after a kidney transplant — this predictability is especially valuable. A patient who cannot reliably report new symptoms or side effects benefits from a drug whose behavior the medical team can monitor through established lab protocols rather than relying heavily on patient self-reporting.
The Cost Factor — Why Generic Cyclosporine Dominates in Much of the World
Cost is one of the bluntest forces keeping cyclosporine in widespread use. Since patent expirations, generic competition has driven prices down 75 to 80% below brand-name versions. Branded oral cyclosporine runs approximately $800 to $1,200 per month, while generics cost $150 to $250 per month. In many developing countries, the price is even lower. This makes cyclosporine the preferred immunosuppressant in resource-limited settings where newer drugs are simply unaffordable. Asia-Pacific markets, especially China and India, are seeing rapid growth in cyclosporine use due to improving healthcare access and rising transplant procedure volumes, according to 6W Research.
In these regions, the choice between cyclosporine and tacrolimus is often not a clinical preference but an economic necessity. A transplant center in rural India may have reliable access to affordable generic cyclosporine but face supply chain difficulties or prohibitive costs for tacrolimus or newer agents like belatacept. The tradeoff is real, though. Cheaper does not mean equivalent in every clinical scenario. The Cochrane data showing tacrolimus’s superiority in reducing acute rejection cannot be ignored. For well-resourced transplant centers with access to both drugs and robust monitoring, tacrolimus is often the first choice for kidney transplantation specifically. The question is whether the modest clinical advantage of tacrolimus justifies its higher cost and its own set of side effects — and in many parts of the world, the answer is no.
Cyclosporine in Dry Eye Treatment — A Separate Market Entirely
Cyclosporine’s role in ophthalmology deserves separate discussion because it operates in an entirely different clinical and commercial context from its systemic uses. Restasis, the branded 0.05% cyclosporine ophthalmic emulsion, was for years one of the most prescribed eye medications in the United States. Its generic version is now available for as low as $62 per month through discount programs, compared to brand Restasis at over $700 per month. Cequa, a higher-concentration 0.09% formulation, costs approximately $850 for 60 single-use vials and has no generic available. Cyclosporine ophthalmic remains a cornerstone of chronic dry eye treatment despite the arrival of newer options like lifitegrast, sold under the brand name Xiidra.
The ophthalmic formulations work by reducing inflammation on the ocular surface and allowing the eye to produce more of its own tears — a fundamentally different approach from artificial tears, which only provide temporary relief. For patients with moderate to severe dry eye disease, this anti-inflammatory mechanism addresses underlying disease rather than just managing symptoms. A warning for caregivers: dry eye disease is significantly underdiagnosed in elderly patients, including those with dementia. Patients with cognitive impairment may not complain of dry, irritated eyes even when the condition is causing significant discomfort or contributing to visual disturbance. If a patient with dementia is rubbing their eyes frequently, blinking excessively, or showing signs of eye irritation, it is worth discussing cyclosporine ophthalmic drops with their ophthalmologist.
Neurological Side Effects — What Caregivers Should Watch For
For readers of a brain health and dementia care site, the neurological side-effect profile of cyclosporine warrants specific attention. While cyclosporine generally causes fewer neurological side effects than tacrolimus according to the Cochrane review data, it is not free of them. Tremor, headache, and in rare cases more serious neurotoxicity including posterior reversible encephalopathy syndrome have been reported with cyclosporine use.
In patients who already have cognitive impairment, these neurological effects can be difficult to distinguish from progression of the underlying condition. A new tremor might be attributed to Parkinson’s disease or advancing dementia when it is actually a medication side effect. Caregivers should ensure that any new neurological symptom in a patient taking cyclosporine is evaluated in the context of the drug, not automatically chalked up to the patient’s existing diagnosis. Regular therapeutic drug monitoring helps here — elevated cyclosporine levels correlate with increased risk of neurotoxicity, and catching a high trough level early can prevent complications.
Where Cyclosporine Goes From Here
Cyclosporine is not going away. The global market is projected to continue growing through at least 2034, driven by expanding transplant volumes in Asia-Pacific countries, the continuing demand for affordable immunosuppression in resource-limited settings, and the ophthalmic dry eye market where new cyclosporine formulations continue to be developed.
More than 65% of healthcare providers already incorporate it into long-term regimens, and that number reflects entrenched clinical comfort rather than mere habit. The more interesting question is whether cyclosporine might find new life in conditions currently under investigation, or whether its role will gradually narrow as newer drugs prove their long-term safety profiles. For now, cyclosporine occupies a position that no single newer drug has managed to fill — affordable, versatile, well-understood, and effective enough across a broad range of conditions that its continued use is not nostalgia but pragmatism.
Conclusion
Cyclosporine’s staying power comes down to a combination of factors that no single newer drug has replicated: a remarkably broad range of approved and off-label indications, decades of therapeutic drug monitoring data that make it predictable and manageable, generic pricing that puts it within reach of healthcare systems worldwide, and a side-effect profile that, while serious, is thoroughly characterized and distinct from its competitors. With more than 2 million prescriptions filled in the United States in 2023 alone, the drug is anything but obsolete.
For caregivers and patients navigating immunosuppressive therapy alongside dementia or other neurological conditions, the key takeaway is that drug selection is always about tradeoffs. Cyclosporine may cause fewer neurological and metabolic side effects than tacrolimus in some patients, but it requires diligent monitoring and carries its own risks, particularly to the kidneys. The best approach is an informed conversation with the prescribing physician about why a specific immunosuppressant was chosen, what monitoring is needed, and what symptoms should prompt a call to the doctor.
Frequently Asked Questions
Is cyclosporine the same as tacrolimus?
No. Both are calcineurin inhibitors that suppress T-cell activation, but they are chemically different drugs with distinct side-effect profiles. Tacrolimus is generally more potent at preventing acute organ rejection but carries higher risks of post-transplant diabetes and neurological side effects compared to cyclosporine.
Why would a doctor choose cyclosporine over tacrolimus for a transplant patient?
Several reasons. The patient may have diabetes or be at high risk for it, since tacrolimus causes 5 additional cases of insulin-requiring diabetes per 100 patients compared to cyclosporine. The patient may have experienced neurological side effects on tacrolimus, or the treatment center may be in a resource-limited setting where affordable generic cyclosporine is the most practical option.
Can cyclosporine affect memory or cognitive function?
Cyclosporine can cause neurological side effects including tremor, headache, and in rare cases more serious neurotoxicity. While it generally has a lower rate of neurological side effects than tacrolimus, any new cognitive or neurological symptoms in a patient taking cyclosporine should be reported to the prescribing physician and evaluated in the context of the drug rather than automatically attributed to an existing condition like dementia.
How much does cyclosporine cost without insurance?
Generic oral cyclosporine costs approximately $150 to $250 per month, compared to $800 to $1,200 per month for brand-name versions. For ophthalmic use, generic Restasis is available for as low as $62 per month through discount programs, while the branded version exceeds $700 per month.
Is cyclosporine used for dry eye disease?
Yes. Cyclosporine ophthalmic drops — available as Restasis (0.05%) and Cequa (0.09%) — are FDA-approved to increase tear production in patients with chronic dry eye disease. Unlike artificial tears, cyclosporine eye drops address the underlying inflammation rather than providing only temporary symptom relief.
